U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H10O4
Molecular Weight 182.1737
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLYCOL SALICYLATE

SMILES

c1ccc(c(c1)C(=O)OCCO)O

InChI

InChIKey=LVYLCBNXHHHPSB-UHFFFAOYSA-N
InChI=1S/C9H10O4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11H,5-6H2

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?dr:D01557

Glycol Salicylate is a nonsteroidal antiinflammatory drug, it is an ingredient of many rubefacient creams and sprays for the relief of aches, pains and stiffness in muscles joints and tendons. It is an analgesic and anti-inflammatory agent, used topically. It is also included in preparations for soothing haemorrhoids. Glycol Salicylate is a component of Salonsip Gel Patch. Salonsip Gel Patch, manufactured by Hisamitsu Pharmaceutical Co., Inc. of Tosu City, Japan, consists of Glycol Salicylate 1.25%, l-menthol 1.00%, Tocopherol Acetate 1.0%, dl-camphor 0.1%.

Originator

Curator's Comment:: Salonsip Gel Patch, containing Glycol Salicylate, was launched in 1934

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Salonsip Gel-Patch

Approved Use

For relief of aches, pains and minor inflammations associated with: ■ muscle fatigue ■ muscle pain ■ stiff shoulder ■ simple backache ■ bruises ■ sprains ■ strains ■ arthritis ■ minor frostbite
Palliative
Percutalgine

Approved Use

For treatment of benign joint conditions such as mild tendinitis, small joint arthritis and sprains.
Doses

Doses

DosePopulationAdverse events​
10 % 1 times / day single, topical
Studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
healthy, 47 years
n = 1
Health Status: healthy
Age Group: 47 years
Sex: M
Population Size: 1
Sources:
Other AEs: Contact dermatitis...
5 % multiple, topical
Studied dose
Dose: 5 %
Route: topical
Route: multiple
Dose: 5 %
Sources:
unhealthy, 64 years
n = 1
Health Status: unhealthy
Condition: cervical pain
Age Group: 64 years
Sex: M
Population Size: 1
Sources:
Other AEs: Contact dermatitis...
Other AEs:
Contact dermatitis
Sources:
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Co-administed with::
arnica tincture(41.5 mg; 5/day; during 10 days)
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Disc. AE: Urticaria, Skin irritation...
Other AEs: Redness, Itching...
AEs leading to
discontinuation/dose reduction:
Urticaria (0.4%)
Skin irritation (0.4%)
Other AEs:
Redness (1.7%)
Itching (1.7%)
Urticaria (1.7%)
Sources:
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Disc. AE: Urticaria, Redness...
AEs leading to
discontinuation/dose reduction:
Urticaria (0.4%)
Redness (0.4%)
Allergic reaction (0.4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Contact dermatitis
10 % 1 times / day single, topical
Studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
healthy, 47 years
n = 1
Health Status: healthy
Age Group: 47 years
Sex: M
Population Size: 1
Sources:
Contact dermatitis
5 % multiple, topical
Studied dose
Dose: 5 %
Route: topical
Route: multiple
Dose: 5 %
Sources:
unhealthy, 64 years
n = 1
Health Status: unhealthy
Condition: cervical pain
Age Group: 64 years
Sex: M
Population Size: 1
Sources:
Skin irritation 0.4%
Disc. AE
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Co-administed with::
arnica tincture(41.5 mg; 5/day; during 10 days)
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Urticaria 0.4%
Disc. AE
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Co-administed with::
arnica tincture(41.5 mg; 5/day; during 10 days)
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Itching 1.7%
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Co-administed with::
arnica tincture(41.5 mg; 5/day; during 10 days)
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Redness 1.7%
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Co-administed with::
arnica tincture(41.5 mg; 5/day; during 10 days)
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Urticaria 1.7%
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Co-administed with::
arnica tincture(41.5 mg; 5/day; during 10 days)
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Allergic reaction 0.4%
Disc. AE
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Redness 0.4%
Disc. AE
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Urticaria 0.4%
Disc. AE
12.5 mg 5 times / day multiple, topical
Studied dose
Dose: 12.5 mg, 5 times / day
Route: topical
Route: multiple
Dose: 12.5 mg, 5 times / day
Sources:
unhealthy, mean age 30.8 years
n = 228
Health Status: unhealthy
Condition: ankle joint distortion
Age Group: mean age 30.8 years
Sex: M+F
Population Size: 228
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Synergetic analgesic effect of the combination of arnica and hydroxyethyl salicylate in ethanolic solution following cutaneous application by transcutaneous electrostimulation.
2003
Patents

Sample Use Guides

Adults and children 12 years of age and over: clean and dry affected area. Remove from backing film and apply to affected area not more than 3 to 4 times daily. Remove after at most 8 hours.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Name Type Language
GLYCOL SALICYLATE
INCI   JAN   MART.   MI   WHO-DD  
INCI  
Official Name English
GLYCOL SALICYLATE [INCI]
Common Name English
2-HYDROXYETHYL SALICYLATE
Systematic Name English
2-HYDROXYETHYL 2-HYDROXYBENZOATE
Systematic Name English
GLYCOL SALICYLATE [MART.]
Common Name English
HYDROXYETHYL SALICYLATE [EP MONOGRAPH]
Common Name English
BENZOIC ACID, 2-HYDROXY-, 2-HYDROXYETHYL ESTER
Common Name English
HYDROXYETHYL SALICYLATE
EP  
Systematic Name English
NSC-72097
Code English
SALICYLIC ACID, 2-HYDROXYETHYL ESTER
Common Name English
GLYCOL SALICYLATE [JAN]
Common Name English
GLYCOL SALICYLATE [MI]
Common Name English
GLYCOL SALICYLATE [WHO-DD]
Common Name English
Code System Code Type Description
CAS
87-28-5
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
DRUG CENTRAL
3269
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
ECHA (EC/EINECS)
201-737-2
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
MESH
C020904
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
RXCUI
26051
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB11323
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
EVMPD
SUB13999MIG
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
PUBCHEM
6880
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
EPA CompTox
87-28-5
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
FDA UNII
3I1VBB7AXH
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY
MERCK INDEX
M5805
Created by admin on Fri Jun 25 21:18:56 UTC 2021 , Edited by admin on Fri Jun 25 21:18:56 UTC 2021
PRIMARY Merck Index